Provided by Tiger Trade Technology Pte. Ltd.

FibroBiologics

0.3124
-0.0277-8.14%
Post-market: 0.31750.0051+1.63%19:56 EDT
Volume:789.31K
Turnover:261.37K
Market Cap:21.12M
PE:-0.75
High:0.3891
Open:0.3400
Low:0.3050
Close:0.3401
52wk High:1.53
52wk Low:0.2201
Shares:67.59M
Float Shares:56.56M
Volume Ratio:0.85
T/O Rate:1.40%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4175
EPS(LYR):-0.4175
ROE:-419.44%
ROA:-79.85%
PB:3.43
PE(LYR):-0.75

Loading ...

FibroBiologics Inc. Held Special Stockholders Meeting

Reuters
·
Feb 24

Nasdaq Grants FibroBiologics Extension to Regain Listing Compliance

Reuters
·
Feb 23

FibroBiologics Granted Extension by Nasdaq to Regain Compliance

GlobeNewswire
·
Feb 23

FibroBiologics CEO Pete O’Heeron to Speak at A4LI’s H-SPAN Summit at Georgetown University

Reuters
·
Feb 10

FibroBiologics Faces Nasdaq Delisting Review After Noncompliance

TIPRANKS
·
Feb 07

FibroBiologics droht Nasdaq-Delisting wegen Nichteinhaltung von Börsenauflagen

Reuters
·
Feb 07

FibroBiologics erhält kanadisches Patent für neuartige Cachexie-Therapie

Reuters
·
Feb 05

Fibrobiologics Announces Issuance of Canadian Patent Covering Novel Fibroblast-Based Treatment for Cachexia

THOMSON REUTERS
·
Feb 05

FibroBiologics CEO to Present at DealFlow Discovery Conference

Reuters
·
Jan 20

FibroBiologics Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Jan 06

FibroBiologics CEO to Present at BFC Global Healthcare Business Development and Investment Conference

Reuters
·
Jan 06

BRIEF-Fibrobiologics Announces Results For Fibroblast Spheroid-Derived Chondrocyte Spheroid Therapy

Reuters
·
Jan 05

FibroBiologics Reports Positive Preclinical Results for FSdC Therapy in Degenerative Disc Disease

Reuters
·
Jan 05

Fibrobiologics Announces Positive Preclinical Results for a Fibroblast Spheroid-Derived Chondrocyte (Fsdc) Spheroid Therapy for Degenerative Disc Disease

THOMSON REUTERS
·
Jan 05

Nasdaq Threatens Delisting of Fibrobiologics Inc. Over Prolonged Low Share Price

Reuters
·
Jan 03

FibroBiologics Price Target Maintained With a $5.00/Share by HC Wainwright & Co.

Dow Jones
·
Jan 02

FibroBiologics Files IND Application with FDA for Psoriasis Therapy

Reuters
·
Dec 31, 2025

Fibrobiologics Files Ind Application With the U.S. FDA to Advance Clinical Development of Cyps317 in Patients With Psoriasis

THOMSON REUTERS
·
Dec 31, 2025

U.S. RESEARCH ROUNDUP-Comerica, Heico, Walmart

Reuters
·
Dec 22, 2025

Fibrobiologics Announces $1.7 Million Registered Direct Offering Priced at-the-Market Under Nasdaq Rules

THOMSON REUTERS
·
Dec 15, 2025